Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Atom Therapeutics logo — Atom Therapeutics Co., Ltd

Atom Therapeutics

Atom Therapeutics Co., Ltd

Founded 2012 China Suzhou, China 4 employees Series D Total: $678.08M Biotechnology, Health Care

General Information

Company Name Atom Therapeutics
Founded Year 2012
Location China Suzhou, China
Founders / Decision Makers
Team member
Employees 4
Industries Biotechnology, Health Care
Funding Stage Series D
Business Model B2B
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Atom Therapeutics. To contact Atom Therapeutics, visit atombp.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Atom Therapeutics compare?

A PDF of Atom Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Atom Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Atom Therapeutics

Atom Therapeutics, established in 2012, is a China-based clinical stage biotechnology company with a mission to develop orally delivered small molecule drugs for inflammatory and metabolic diseases. Its focus on conditions like chronic gout, which currently lack effective treatments, sets it apart in the Biotechnology and Health Care industries.

The company’s leading drug candidate, ABP-671, is designed to treat chronic gout. It boasts higher potency and reduced toxicity compared to existing options and is scheduled for global Phase 3 trials in 2022. Additionally, ABP-6016 has shown promise in preclinical trials for treating NASH, potentially addressing a growing cause of liver diseases.

Most recently, Atom Therapeutics secured a CNY600.00M Series D investment on 16 October 2023. The round was led by prominent investors including Kaitai Capital, NNFE Fund Management, Fortune Capital, Unifortune, and HuaJin Securities, reflecting strong confidence in the company's innovative pipeline.

Business keywords: clinical-stage, orally delivered drugs, small molecule drugs, inflammatory diseases, metabolic diseases, chronic gout treatment, NASH treatment, drug development, preclinical trials, Phase 3 trials, non-alcoholic steatohepatitis, liver disease

Services & Products

drug development
clinical trials
pipeline management

Target Customers

patients with gout patients with hyperuricemia patients with cardiovascular diseases healthcare professionals pharmaceutical partners

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series D CNY600.00M 5
Kaitai Capital NNFE Fund Management Fortune Capital
Kaitai Capital, NNFE Fund Management +3
16 Oct 2023
Series C $45.00M 5
Kaitai Capital
Kaitai Capital, ShenZhen GTJA Investment Group +3
05 Jan 2022
Series B $30.00M -
27 May 2020
Series A $3.08M -
21 Jun 2018
Series A Undisclosed -
01 Jun 2017

Atom Therapeutics Alternatives & Competitors

View All Alternatives
Atom Therapeutics vs
Treadwell Therapeutics, Inc.
Treadwell Therapeutics, Inc. United States

The Path to Better

Series B
14 employees
Biotechnology, Health Care
Atom Therapeutics vs
Seal Rock Therapeutics
Seal Rock Therapeutics United States

Developing new drugs for liver disease and other diseases with few or no current therapies

Venture round
7 employees
Biotechnology, Health Care
Atom Therapeutics vs
Intercept Pharmaceuticals
Intercept Pharmaceuticals United States

Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases.

Post-IPO Debt
376 employees
Biotechnology, Health Care
View all alternatives

FAQ About Atom Therapeutics

Atom Therapeutics Co., Ltd
Atom Therapeutics was founded in 2012.
Atom Therapeutics is headquartered in Suzhou, China.
Atom Therapeutics operates in Biotechnology and Health Care. Its work centres on clinical-stage, orally delivered drugs, small molecule drugs and inflammatory diseases. Its customers include patients with gout, patients with hyperuricemia and patients with cardiovascular diseases.
Atom Therapeutics has a B2B business model. Its revenue comes from Licensing and Product Sales.
Atom Therapeutics has approximately 4 employees.
Atom Therapeutics has completed 5 funding rounds, raising a total of $678.08M. The latest funding stage is Series D.
Atom Therapeutics offers: drug development, clinical trials, pipeline management.
Top alternatives and competitors to Atom Therapeutics include Treadwell Therapeutics, Inc., Seal Rock Therapeutics, Intercept Pharmaceuticals, Reviva Pharmaceuticals, Summit Clinical Research. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Atom Therapeutics and Treadwell Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Atom Therapeutics, https://bouncewatch.com/company/atom-bioscience, updated 1 April 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes